日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)

一项 2 期随机、双盲、安慰剂对照研究，旨在评估 soticlestat 作为 Dravet 综合征或 Lennox-Gastaut 综合征患儿辅助治疗的疗效和安全性 (ELEKTRA)

期刊:Epilepsia
影响因子:6.6
doi:10.1111/epi.17367
Hahn, Cecil D; Jiang, Yuwu; Villanueva, Vicente; Zolnowska, Marta; Arkilo, Dimitrios; Hsiao, Samuel; Asgharnejad, Mahnaz; Dlugos, Dennis
发表日期：2022
文献求助 收藏

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials

Dravet综合征患者大麻二酚治疗起效时间：两项随机对照试验的分析

期刊:Epilepsia
影响因子:6.6
doi:10.1111/epi.16974
Madan Cohen, Jennifer; Checketts, Daniel; Dunayevich, Eduardo; Gunning, Boudewijn; Hyslop, Ann; Madhavan, Deepak; Villanueva, Vicente; Zolnowska, Marta; Zuberi, Sameer M
发表日期：2021
文献求助 收藏

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial

Dravet综合征患者长期使用大麻二酚治疗：一项开放标签扩展试验

期刊:Epilepsia
影响因子:6.6
doi:10.1111/epi.14628
Devinsky, Orrin; Nabbout, Rima; Miller, Ian; Laux, Linda; Zolnowska, Marta; Wright, Stephen; Roberts, Claire
发表日期：2019
文献求助 收藏